Concepedia

Target Combination Design

Target Combination Design is a strategic framework in multi-target drug design that identifies and validates optimal sets of biological targets intended to be modulated simultaneously by a therapeutic agent to achieve enhanced efficacy, reduced resistance, or minimized side effects compared to single-target approaches.

12

Publications

283

Citations

66

Authors

29

Institutions

Publications per year

2017–2026

7

Parents

Publications

12

Projectile target combination to synthesis superheavy nuclei Z = 126

H.C. Manjunatha, K.N. Sridhar · Nuclear Physics A · 2017 · 48 citations

, , +7

Optimal reaction for synthesis of superheavy element 117

Z. H. Liu, Jing-Dong Bao · Physical Review C · 2009 · 33 citations

, , +6

Neutrino physics opportunities with the IsoDAR source at Yemilab

J. Alonso, C. Argüelles, Adriana Bungau et al. · Physical review. D/Physical review. D. · 2022 · 32 citations · Full text

, , +15

Targeted drug combination therapy design based on driver genes

Lilian Zsákai, Anna Sipos, Judit Dobos et al. · Oncotarget · 2019 · 28 citations · Full text

, , +13

Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy

Sang‐Min Park, Chae Young Hwang, Jihye Choi et al. · Oncogene · 2020 · 25 citations

, , +17

1–5 of 12

Authors

66

  1. JM
    J. M. Conrad

    Stockholm University, Sweden

    1 publications · 32 citations

    1

    h-index

  2. VK
    V Keeling

    University of Oklahoma Health Sciences Center, United States

    1 publications · 16 citations

    1

    h-index

  3. RP
    Renata Pasqualini

    The University of Texas MD Anderson Cancer Center, United States

    1 publications · 22 citations

    1

    h-index

  4. EM
    E. Marzec

    University of Michigan, United States

    1 publications · 32 citations

    1

    h-index

  5. BD
    Bhaskar Dutta

    Texas A&M University, United States

    1 publications · 32 citations

    1

    h-index

1–5 of 66

Institutions

29

  1. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    1 h-index

    4 publications

    48 citations

  2. University of California, San Francisco

    San Francisco, United States

    1 h-index

    2 publications

    32 citations

  3. Hunan Normal University

    Changsha, China

    1 h-index

    1 publications

    17 citations

  4. George Washington University

    Washington, United States

    1 h-index

    1 publications

    22 citations

  5. AstraZeneca (Sweden)

    Södertälje, Sweden

    1 h-index

    2 publications

    24 citations

  6. Hong Kong Baptist University

    Hong Kong, Hong Kong

    1 h-index

    2 publications

    42 citations

  7. University of Michigan

    Ann Arbor, United States

    1 h-index

    3 publications

    96 citations

  8. Institute for Basic Science

    Daejeon, South Korea

    1 h-index

    2 publications

    64 citations

1–8 of 29

Venues

  1. European Journal of Medicinal Chemistry

    1 publications · 21 citations

    1

    h-index

  2. Analytica Chimica Acta

    1 publications · 16 citations

    1

    h-index

  3. Technology in Cancer Research & Treatment

    TCRT · 1 publications · 16 citations

    1

    h-index

  4. Physical review. D/Physical review. D.

    PRD · 1 publications · 32 citations

    1

    h-index

  5. Oncotarget

    1 publications · 28 citations

    1

    h-index

1–5